+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Becker Muscular Dystrophy Pipeline Analysis and Outlook, 2019

  • ID: 4772573
  • Report
  • 45 pages
  • VPA Research
1 of 4

FEATURED COMPANIES

  • Armgo Pharma Inc
  • Cardero Therapeutics Inc
  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • MORE
Becker Muscular Dystrophy pipeline

Becker Muscular Dystrophy pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Becker Muscular Dystrophy R and D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Becker Muscular Dystrophy report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Becker Muscular Dystrophy as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Becker Muscular Dystrophy with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Becker Muscular Dystrophy pipeline Profiled in detail

Key players actively participating in Becker Muscular Dystrophy pipeline are profiled along with their R&D progress in Becker Muscular Dystrophy treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Becker Muscular Dystrophy pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Becker Muscular Dystrophy treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Becker Muscular Dystrophy pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Becker Muscular Dystrophy pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Becker Muscular Dystrophy pipeline study
  • All recent news and developments related to Becker Muscular Dystrophy drugs are provided
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Armgo Pharma Inc
  • Cardero Therapeutics Inc
  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Becker Muscular Dystrophy Disease Overview

3. Becker Muscular Dystrophy Research and Development Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Becker Muscular Dystrophy Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Becker Muscular Dystrophy Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Becker Muscular Dystrophy companies
6.1.1 Business Profile
6.1.2. Pipeline Products
6.1.3. Becker Muscular Dystrophy Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Armgo Pharma Inc
  • Cardero Therapeutics Inc
  • Catabasis Pharmaceuticals Inc
  • Italfarmaco SpA
  • Milo Biotechnology LLC
  • PTC Therapeutics Inc
  • ReveraGen BioPharma Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4772573
Adroll
adroll